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Abstract Hemostasis is a major problem in surgical procedures and after major trauma. There are few effectiveU
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EDmethods to stop bleeding without causing secondary damage. We used a self-assembling peptide thatestablishes a nanofiber barrier to achieve complete hemostasis in less than 15 seconds when applieddirectly to a wound in the brain, spinal cord, femoral artery, liver, or skin of mammals. This noveltherapy stops bleeding without the use of pressure, cauterization, vasoconstriction, coagulation, or
cross-linked adhesives. The self-assembling solution is nontoxic and nonimmunogenic, and the
breakdown products are amino acids, which are tissue building blocks that can be used to repair the site
of injury. Here we report the first use of nanotechnology to achieve complete hemostasis in less than 15
seconds, which could fundamentally change how much blood is needed during surgery of the future.D 2006 Published by Elsevier Inc. E
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ORThrough the ages doctors have found ways to achievehemostasis, beginning with the simple act of applyingpressure, then cauterization, ligation, and clinically induced
vasoconstriction [1-10], but nanotechnology brings new
possibilities for changes in medical technology. Here we
present a novel method to stop bleeding using materials that
self-assemble at the nanoscale when applied to a wound. This41
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tledg@mit.edu (R.G. Ellis-Behnke).method results in the formation of a nanofiber barrier that
stops bleeding in any wet ionic environment in the body;
furthermore, the material is broken down into natural l-amino
acids that can be used by the surrounding tissue for repair.
Currently there are three basic categories of hemostatic
agents or procedures: chemical, thermal, and mechanical
[1,3,6,8,10-15]. Chemical agents are those that change
the clotting activity of the blood or act as vasoconstrictors,
such as thromboxane A2 [16], which causes vessels to
contract thus reducing blood flow and promoting clotting
[7,16,17]. Thermal devices commonly involve cauterization
using electrodes, lasers [8,14], or heat. There are also agents
that react exothermically upon application that may
create an effect similar to a standard two probe cautery
device [1,14]. Mechanical methods use pressure or ligature
to slow the blood flow [3]. A combination therapy might use
both chemical and mechanical means to produce a he-
mostat that adsorbs fluid and swells [18], producing
pressure to slow the blood flow and allow clotting, or it
may involve the introduction of fibrinogen, thrombin, andlogy, and Medicine xx (2006) xxx–xxx
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Fig 1. Schematics of surgical procedures. Rostral is up and caudal is down in all figures. A, Dorsal view of the rat brain. The blue lines depict the blood vessels
superficial to the cortex. The boxed area corresponds to location of the lesion and treatment. B, Drawing of ventral view of the lower limb of a rat with the
femoral artery in red and sciatic nerve in yellow. C and D, Drawings of a ventral view of rat with abdomen open. Overlying structures have been removed
exposing the liver. The lobe was transected with a cut (depicted in red) in both sagittal (C) and transverse (D) directions.
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calcium to produce fibrin glue, which acts as an artificial
clot [1,2,5,6,8,10,14,19].
There are five major issues related to the limitations and
applicability of many of these hemostatic agents. First, some
of the materials are solid, such as powder formulations, and
are not able to flow into the area of injury to bring about their
hemostatic effects [1,10,14]; second, some liquid agents,
such as cyanoacrylates, require a dry environment to be
effective [8]; third, some materials can create an immune
response resulting in the death of adjacent cells, placing ad-
ditional stress on the body that can prolong or prevent healing
[8,10,14,15,20]; fourth, some agents have a short shelf-life
and very specific handling requirements [6,10,14,16,17]; and
finally, many currently used hemostats are difficult to use in
uncontrolled environments [1,7,8,10,14]. Moreover, if a
therapy uses swelling as part of its hemostatic action, then
extra care must be taken to ensure that the local blood supply
is not reduced or stopped, which could cause additional tissue
damage or even death. This is particularly crucial when using
expanding foams [19]. Many hemostatic agents must be
prepared just before use because of their short shelf-life.
Surgical instruments, such as cauterization devices, clamps
and clips, must be used by a skilled individual in a controlled
environment [2,5,8-10,16,20].
Our discovery, observed during a neurosurgical proce-
dure, introduces a new way to stop bleeding using a self-
assembling peptide that establishes a nanofiber barrier and
incorporates it into the surrounding tissue to form an
extracellular matrix (ECM). Surmising that nanotechnology
might be useful in our central nervous system regeneration
studies, we injected the material into wound sites in the brain
of hamsters to determine whether it would facilitate neuronal
regeneration [21]. To our surprise, it also stopped bleeding.
We then wanted to know if the rapid hemostasis that we
had observed in our nerve regeneration experiments was
tissue specific or would also work in other tissues. The sevenED
 Pexperiments we designed and performed demonstrate that in
less than 15 seconds complete hemostasis can be achieved
after (1) a transection of a blood vessel leading to the superior
sagittal sinus in both hamsters and rats, (2) a spinal cord cut,
(3) a femoral artery cut, (4) a sagittal transection of the left
lateral liver lobe, (5) a transverse transection of the left lateral
liver lobe including a cut in a primary branch of the portal
vein, (6) a 4-mm liver punch biopsy, and (7) multiple 4-mm
skin punch biopsies on nude mice.Materials and methods
Adult Syrian hamsters were anesthetized with an intra-
peritoneal injection of sodium pentobarbital (50 mg/kg), and
adult rats were anesthetized with an intraperitoneal injection
of ketamine (50 mg/kg). The experimental procedures
adhered strictly to the protocol approved by the Department
of Health and endorsed by the Committee on the Use of
Laboratory Animals for Teaching and Research of the
University of Hong Kong and the Massachusetts Institute
of Technology Committee on Animal Care.
Cortical vessel cut experiment
The animals were fitted in a head holder. The left lateral
part of the cortex was exposed, and each animal received a
transection of a blood vessel leading to the superior sagittal
sinus (Figure 1, A). With the aid of a sterile glass micro-
pipette, 20 lL of 1% NHS-1 solution (see below under
bPreparation of the self-assembling solutionsQ) was applied to
the site of injury or iced saline in the control cases. The
animals were allowed to survive for as long as 6 months.
Spinal cord injury experiment
Under an operating microscope, the second thoracic
spinal cord segment (T2) was identified before performing a
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Fig 2. Complete hemostasis in brain and femoral artery. The pictures are time-lapse images at each stage of the experiment for brain (A -D) and femoral artery
(E-H). A-D, Adult rat cortex hemostasis. Part of the Q6overlying skull has been removed in an adult rat, and one of the veins of the superior sagittal sinus is
transected and treated with 1% self-assembling NHS-1. A, The brain and veins of the superior sagittal sinus (SSS) are exposed. B, Cutting of the vein (arrow).
C, Bleeding of the ruptured vein (arrow). D, The same area 5 seconds after application of the self-assembling NHS-1 to the location of the cut (arrow) as seen
under the clear NHS-1. E-H, Rat femoral artery hemostasis. Exposure of the neurovascular bundle in the thigh showing the sciatic nerve (*) in each panel. E,
Femoral artery and vein exposed. F, Cutting of the artery (arrow). G, Bleeding, masking the artery completely and sciatic nerve partially. H, The same area 5
seconds after application of the self-assembling peptide to the cut (arrow). Note that there is complete hemostasis in the area formed by NHS-1 (covering the
entire picture) as it self-assembles in the presence of blood and plasma, revealing the underlying structures. Complete hemostasis was achieved in 10.6 F 4.1
seconds, significantly different from 367.5 F 37.7 seconds in controls irrigated with saline ( P N .0001). Scale bars represent 1 mm.
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dorsal laminectomy in anesthetized adult rats [22,23]. After
opening the dura mater, we performed a right hemisection
using a ceramic knife. Immediately after the cord hemi-
section 20 lL of a 1% solution of NHS-1 was applied to the
area of the cut for bleeding control. The controls received a
saline treatment. The animals were allowed to survive for as
long as 8 weeks as part of another experiment.
Femoral artery cut experiment
Rats were placed on their backs, and the hind limb was
extended to expose the medial aspect of the thigh (Figure 1,
B). The skin was removed, and the overlying muscles were
cut to expose the femoral artery and sciatic nerve. The
femoral artery was cut to produce a high-pressure bleeder
(Figure 2, F). With a 27-gauge needle, 200 lL of 1% NHS-
1 solution was applied over the site of injury. In two cases
we applied the dry powder of NHS-1 to the injury site,
which also was effective. (Data are not shown and were not
included in the analysis.) Controls were treated with a
combination of saline and pressure with a gauge. All
animals were killed 4 hours after the experiment.
Liver wound experiments
Rats were anesthetized and placed on their back, and
the abdomen was opened exposing the liver (Figure 1, C).
The left lobe of the liver was cut using a scalpel in the
rostral-to-caudal direction, separating the two halves of the
lobe (Figure 3, B) in the sagittal cut. With a 27-gauge
needle, 100 lL of 1% or 2% NHS-1, NHS-2, or TM-3
solution was applied to the site of injury (Figure 3, B).
Livers of the controls were treated with saline or
cauterized. Cauterization was performed using a thermalTEcautery device and was applied to the entire surface of theinjury. In another group of 28 adult rats the sameprocedure was followed for the liver, which was cut
transversely (Figure 3, D). With a 27-gauge needle, 400 lL
of 1%, 2%, 3%, or 4% NHS-1 or TM-3 solution was applied
to the site of injury (Figure 3, H).
In another group of anesthetized adult rats the liver was
exposed, and a 4-mm punch biopsy done from the ventral
aspect through the liver to the dorsal surface of the left liver
lobe. The resulting core was removed from the liver, after
which one of three treatments was applied. For the treatment
group 200 lL of 3% NHS-1 solution was applied to the site
of injury, whereas in the controls either saline was applied or
cauterization of the exposed liver surface was carried out.
The superficial material was then wiped clear of the injury
site. The abdominal incision was closed, and the animals
were allowed to survive for as long as 8 weeks.
Skin punch experiment
In anesthetized adult nude mice using aseptic precautions,
a 4-mm punch was used to create three wounds on each side
of the back of the animal. On one side of the animal the
wounds created were treated with 1% NHS-1 solution, and
the wounds on the opposite side were left untreated to provide
a control. The punch biopsies were made through the full
thickness of the skin. If the wound did not bleed for
10 seconds the punch would be excluded from the data
analyzed. All procedures were videotaped, and the analysis
consisted of reviewing the tapes. The animals were allowed to
survive for as long as 2 months. If animals involved in any of
the above experiments appeared to experience any discomfort
they were euthanized.
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Fig 3. Rat liver hemostasis. This series of pictures is of an adult rat wherein the skin covering the intraperitoneal cavity was excised, exposing the liver. A -D,
Sagittal cut. A, The left lateral lobe received a sagittal cut completely transecting a portion of the liver lobe. B, The liver is separated (arrow). Note the profuse
bleeding. C, The two halves are allowed to come back together, and the bleeding continues (arrow). D, The 1% NHS-1 solution was applied, and the extent of
the incision was visible under the transparent assembled NHS-1 (arrow). Complete hemostasis was achieved in 8.6F 1.7 seconds, statistically significant when
compared to 90.0 F 5.0 seconds when cauterization was applied, or 301.6 F 33.2 seconds if irrigated with saline. E -J, Transverse cut. This series of pictures
is of a transverse cut to the left lateral lobe in an adult rat. E, The exposed intact liver. F, Applying a transverse cut in the lobe (arrow). G, Profuse bleeding
produced when a major branch of the portal vein is cut (arrows). H, Treatment with self-assembling NHS-1. Note the complete cessation of bleeding (in 10.3F
0.5 seconds using 2% concentration; 10.0 F 1.0 seconds and 11.0 F 1.0 using 3% and 4%, respectively) seen under the clear assembled NHS-1 (arrow). I, 2
minutes after treatment and after the superficial self-assembling NHS-1 has been removed (arrows) to show the extent of cut. J, Bleeding had ceased 15
minutes after NHS-1 treatment. Scale bars represent 1 mm.
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Transmission electron microscopy sample preparation
In the brain and liver of anesthetized adult rats a 1% or
2% NHS-1 solution was injected immediately after making
a cut, and the treatment site was sampled. Samples were
fixed in a mixture of 2% paraformaldehyde and 2.5%
glutaraldehyde in 0.1 M phosphate buffer (PB) for 4 hours.
The samples were washed in 0.1 M PB three times for
10 minutes each at 48C and embedded in 2% agar; blocks
were postfixed in 48C 1% osmium tetroxide for 2 hours and
then washed in buffer three times for 10 minutes each at
48C. The sample blocks were dehydrated in ethanol,
infiltrated, and embedded in pure epon with Lynx EM
tissue processor. Ultrathin 70-nm sections were cut (Reich-
ert-Jung ultra cut) and collected on no. 200 mesh grids.
Sections and grids were stained with uranyl acetate and lead
citrate and examined under a Philip EM208S transmission
electron microscope.Preparation of the self-assembling solutions
The NHS-1 solution was prepared using RADA16-I
2synthetic dry powder (obtained from the Massachusetts
2Institute of Technology Center for Cancer Research
2Biopolymers Laboratory, Cambridge, MA; the Zhang
2laboratory, and 3-DMatrix, Cambridge, MA) dissolved in
2an Eppendorf tube. The 1% NHS-1 solution was prepared
2by dissolving 10 mg of RADA16-I powder in 1 mL of
2autoclaved Milli-Q water (Millipore Corp., Billerica, MA),
2sonicated for as long as 5 minutes, and filtered. This was
2repeated with 20 mg/mL, 30 mg/mL, and 40 mg/mL to
2produce 2%, 3%, and 4% concentrations. NHS-2 and TM-3
2dry powders (made by the Massachusetts Institute of
2Technology Center for Cancer Research Biopolymers
2Laboratory, Cambridge, MA) were prepared using the same
2method. The time of preparation did not affect the action of
2the solution. We also tested some material that was prepared
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Fig 4. Time required to achieve hemostasis. Graphs illustrate bleeding Q15durations in cases treated with 1% NHS-1 self-assembling solution compared with those
cautery- and saline-treated controls for brain, femoral artery, and liver cuts (A), liver punches (B), and skin punches (C). Each bar shows the mean time in
seconds for NHS-1–treated cases (in red), saline controls (in blue), and cautery controls (in yellow). A, In the rat brain cut, durations were measured from the
start of application of self-assembling NHS-1 to the completion of hemostasis after transection of the veins leading to the superior sagittal sinus in the brain of
adult rats. Complete hemostasis was achieved in 8.4 F 2.1 seconds. In the saline controls bleeding continued until 227.0 F 36.6 seconds. In the hamster brain
cut, complete hemostasis was achieved in 9.0 F 1.8 seconds. In the saline controls bleeding continued until 187.6 F 34.7 seconds. In the femoral artery cut,
complete hemostasis was achieved in 10.5 F 4.1 seconds. In the saline controls bleeding continued until 367.5 F 37.7 seconds. In the liver sagittal cut,
complete hemostasis was achieved in 8.6 F 1.7 seconds. In the cautery control (yellow), bleeding continued until 90.0 F 5.0 seconds, and the saline controls
bled for 301.6 F 33.2 seconds. B, Liver 4-mm punch biopsy. A 4-mm core was removed from the left liver lobe, and the hole was treated with NHS-1, heat
cautery, or saline. Treatment with 3% NHS-1 brought about complete hemostasis in 9.7 F 1.2 seconds. In the cautery controls (yellow) bleeding continued for
81.2F 6.7 seconds, and the saline controls bled for 204.3F 49.6 seconds. , Skin 4-mm punch biopsy. A 4-mm punch biopsy was made on the backs of nude
mice. The biopsy extended through the dermis, and the core was removed. Care was taken not to disrupt the underlying muscle. The three wounds on one side
were treated with 1% NHS-1, and complete hemostasis was achieved in 6.4 F 1.5 seconds. On the opposite side of the animal the wounds were not treated.
Bleeding continued until normal clotting occurred at 75.5 F 16.3 seconds. D, Concentration response curves of NHS-1 and TM-3. The left lateral liver lobe
received a transverse cut severing a portion of the liver lobe and branch of the portal vein. A higher concentration of NHS-1 (open circles) is more effective in
higher pressure and volume hemorrhages. NHS-1 at concentrations of 4%, 3%, and 2% were effective in achieving hemostasis in 11.0 F 1.0 seconds, 10.0 F
1.0 seconds, and 10.3 F 0.5 seconds, respectively. The 1% NHS-1 solution required 86.6 F 20.8 seconds at the area of the most severe bleeding. TM-3
(diamonds) was not effective at any concentration; in the saline controls bleeding continued until 377.5F 85.0 seconds, and one animal died. Time (seconds) is
shown on the x-axis, concentration on the y-axis.
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performed as well as the newly mixed material.
Results
Hemostasis in a brain injury
We began our experiments in the brain, removing the
overlying skull and performing a complete transection of a
branch of the superior sagittal sinus in the brain of rats (n =
15) and hamsters (n = 15) (Figure 1, A). The areas were
treated with 20 lL of a 1% solution of RADA16-I (NHS-1)
self-assembling solution or with iced saline. In the groups
treated with NHS-1 hemostasis was achieved in less than 10
seconds in both hamsters and rats (Figure 2, A-D and
Supplemental Video 1, bHemostasis in rat cortex with self-
assembling peptide treatmentQ). Control group hamsters
(n = 5) and rats (n = 5) irrigated with saline bled for more
than 3 minutes (Figure 4, A). A truncated iced-saline control2and subsequent treatment with NHS-1 is shown in
2Supplemental Video 2 (bSaline control and treatment with
2self-assembling peptide in rat cortex.Q) StudentTs t-test for
2two independent samples in both hamsters and rats showed
2highly significant differences (P b .0001).
2Hemostasis in a spinal cord injury
2Because blood has been shown to be toxic in neural tissue
2[24] we wanted to know if the spinal environment was
2different from the brain. By quickly bringing bleeding under
2control secondary damage caused by surgery can be reduced.
2After laminectomy and removal of the dura, the spinal cord
2was hemisected at T2, from the dorsal to ventral aspect,
2and treated (n = 5) with 20 ll of 1% NHS-1. Hemostasis
2was achieved in just over 10 seconds. In the saline controls
2(n = 5) bleeding continued for as long as 5 minutes.
2Comparison of the treated group and the saline controls
2shows a significant difference using the Tukey test with a
299% confidence interval.
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Fig 5. Electron micrographs. This series of TEM images shows the interactions of NHS-1 with liver, cortex, and red blood cells. A, The left lateral lobe was
treated with NHS-1, and the tissue was taken shortly after treatment. Note the hepatocyte and its nucleus (HN). There is a red blood cell (RBC) between the
assembled NHS-1 (N-1) fields. Scale bar represents 2 Am. B, A closer look at the interface of the RBC and the material. Scale bar represents 50 nm. C, In the
liver the RBC do not appear to mix with the NHS-1. Scale bar represents 1 Am. D, Application of 1% NHS-1 solution to a cut in the cortex. Note the close
interface with the axons (Ax). Scale bar represents 0.2 Am. E, In another part of the brain the interface between the RBC and the NHS-1 appears to be similar to
that in the liver. Scale bar represents 0.1 Am.
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CHemostasis in a high-pressure femoral artery wound
The femoral artery of 14 adult rats was surgically exposed,
transacted, and then treated with 200 lL of a 1% solution of
NHS-1 or iced saline and packing (Figure 2, E-H). In the
treated rats (n = 10) about 10 seconds elapsed before
hemostasis occurred (Figure 4, A). The controls (n = 4)
continued to bleed for more than 6 minutes. The difference in
times to achieve complete hemostasis was highly significant
(StudentTs t-test P b .0001).
Hemostasis in highly vascularized liver wounds
Using a group of 76 rats, we performed three different
liver cuts: (1) a sagittal (rostrocaudal) cut (Figure 3, A and
B) to test NHS-1 in an irregular-shaped laceration wound,
(2) a transverse (lateral-medial) cut involving the transection
of a major branch of the hepatic portal vein to intensify
bleeding (Figure 3, E-J), and (3) 4-mm punches through the
liver lobe to observe the material in uniform wounds.2In the first liver experiment we made a sagittal cut in the
2left lobe (n = 8); upon treatment with 100 lL of 1% NHS-1
2solution bleeding ceased in less than 10 seconds (Figure 3,
2A-D and Supplemental Video 3, bSagittal cut of left liver
2lobe using 1% self-assembling peptide treatmentQ). In one
2set of controls (n = 3) bleeding stopped 90 seconds
2(Figure 4, A) after cauterization of the wound; in the
2saline-treated control animals (n = 3) bleeding continued
2for more than 5 minutes. Comparison of the cauterized and
2the saline-treated controls shows a significant difference
2using the Tukey test with a 99% confidence interval.
2In the second experiment we severed a major branch of the
2portal vein while making a transverse cut in the left lobe to
2test NHS-1 in a environment with a high flow rate. Four
2concentrations of NHS-1 were tested (n = 12) along with
2(n = 4) control animals. We applied 400 lL of 4%
2concentration NHS-1, and bleeding stopped in 11 seconds
2(Figure 3, E-J and Supplemental Video 4, bTransverse cut of
2left liver lobe using 4% self-assembling peptide treatmentQ).
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We duplicated the test successfully with 400 lL of both 3%
and 2% NHS-1 solution; bleeding ceased in 10 and
10.3 seconds, respectively (Figure 4, D). When 400 lL of
1% NHS-1 was applied, bleeding continued for more than
60 seconds (Figure 4, D). The controls, however, bled for
more than 6 minutes. The dose response shows that treatment
results using 3% and 4% NHS-1 are nearly the same as with
the 2% concentration. Furthermore, in the 2%, 3%, and 4%
concentration treatment cases complete hemostasis was
maintained after removing the excess assembled NHS-1
material (Figure 3, I and J). We found that the higher blood
pressure/flow rate transverse liver cut required a concentra-
tion of 2% NHS-1 or higher to bring about complete
hemostasis in less than 15 seconds. A significant difference
was found between the NHS-1–treated and control groups
using analysis of variance (ANOVA). When each treatment
group was compared to the control group those differences
were also significant; a Tukey test showed a 99% confidence
interval. There was no significant difference when the
various NHS-1 concentrations were compared, except for
the 1% NHS-1 solution treatment group.
In the third experiment using adult rats (n = 45) we
punched 4-mm holes through the left lateral lobe and then
treated the area with 3% NHS-1, saline, or heat cautery to
bring about hemostasis (Figure 4, B). In the experimental
group (n = 15) we applied a solution of 3% NHS-1 after
injury and hemostasis was achieved in about 10 seconds,
whereas the saline controls (n = 15) required 3.5 minutes to
stop bleeding. In the heat cautery control group (n = 15)
cessation of bleeding took more than 60 seconds, inclusive of
applying heat to cauterize the inside surface of the punch. We
allowed the NHS-1–treated animals to survive for as long as 6
months with no detrimental effect on the tissues. Using
ANOVA there was a significant difference between the 3%
NHS-1 treatment and the controls (P b .0001). In addition,
the Tukey test showed that each group was significantly
different from the other with a 99% confidence interval.
Hemostasis in skin punch biopsies
Six 4-mm punch biopsies were made on the backs of each
of 23 anesthetized adult nude mice for a total of 138 punches.
Three punches were treated with 1% NHS-1 solution and the
other three were left untreated, except for dabbing with cotton
every 15 seconds until bleeding stopped. Punched wounds
that bled for less than 10 seconds were excluded from the
experiment. We applied a solution of 1% NHS-1 10 seconds
after injury (n = 23), and hemostasis took less than
10 seconds; the controls (n = 23) continued to bleed for
more than 60 seconds (Figure 4, C). The bleeding times were
averaged for each side of the animal, and the StudentTs t-test
for paired samples showed a significant difference between
the treatment and control side of the animal (P b .0001).
Comparison of three different materials
To learn more about the hemostatic properties and
mechanism of action of NHS-1 (RADA-16), we repeatedTE
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3both the sagittal and transverse liver experiments, comparing
3them with two additional materials that are known to self-
3assemble and spontaneously form nanofibers: (1) RADA-12
3(NHS-2), a sequence variation of NHS-1, and (2) EAK-16
3(TM-3), a different sequence in the same family of self-
3assembling peptides used to determine if the materialTs
3length and stiffness altered its hemostatic effectiveness in
3bleeding models [25-31].
3Making a sagittal liver cut in adult rats (n = 9) we
3applied 100 lL of 2% NHS-2 solution to the wound, and
3bleeding stopped in less than 10 seconds. In the cautery
3controls (n = 3) bleeding continued for more than
390 seconds (P b .0001). Upon repetition of the experiment
3in adult rats (n = 8) using 100 lL of 2% TM-3, the material
3assembled but did not achieve hemostasis; the animals
3continued to bleed until the experiment was terminated after
3more than 3 minutes.
3The increased blood flow from the portal vein after
3making a transverse liver cut allowed us to perform another
3dose response experiment in which we compared various
3concentrations of NHS-1 (1% to 4%) and TM-3 (1% to 3%)
3with controls (Figure 4, D). All concentrations of NHS-1
3were effective; however, the higher blood pressure and flow
3rate after the transverse liver cut required a concentration of
32% or higher of NHS-1 to stop bleeding in less than
315 seconds.
3TM-3 is a stiffer gel; 1% TM-3 is similar in stiffness to
33% NHS-1. We tried three different concentration levels
3(1%, 2%, and 3%) and found that TM-3 was not effective at
3any concentration; the assembled material fractured and the
3TM-3–treated animals continued to bleed regardless of the
3concentration used. There was actually no significant
3difference between TM-3 and the controls (Figure 4, D) in
3achieving hemostasis.
3Interface of NHS-1 and tissues
3Still looking for mechanism clues as well as further
3understanding of the relationship of the NHS-1 blood/tissue
3interface in both the brain and liver, we also examined the
3treated tissues using transmission electron microscopy
3(TEM), interested in learning how the red blood cells (RBCs),
3platelets, tissue, and the ECM interact with the material.
3We applied 1% NHS-1 to a liver wound and immediately
3harvested the tissue. In the electron micrograph the hepato-
3cyte and RBC looks to be intact with the assembled NHS-1 at
3the interface (Figure 5, A). When applied shortly after injury,
3the material appeared to stop the movement of blood from the
3vessels without detrimental effects to the liverTs RBCs; there
3was also no evidence of lysing (Figure 5, B). Furthermore,
3there was no evidence of platelet aggregation [32] at the
3blood/NHS-1 interface (Figure 5, C) when samples were
3taken at various time points after treatment.
3In the brain we found a very tight interaction between
3NHS-1 and the neural tissue (Figure 5, D). We observed no
3RBCs and no evidence of platelet aggregation in the
3assembled NHS-1. The RBCs that were present appeared
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intact at the edges of the assembled NHS-1 with no evidence
of lysing (Figure 5, E). Furthermore, no evidence of thrombi
was observed in the brain, lung, or liver of the animals
treated with NHS-1 and NHS-2.
Discussion
Our study demonstrates that hemostasis can be achieved in
less than 15 seconds in multiple tissues as well as a variety of
different wounds. This is the first time that nanotechnology
has been used to stop bleeding in a surgical setting for animal
models and seems to demonstrate a new class of hemostatic
agent that does not rely on heat, pressure, platelet activation,
adhesion, or desiccation to stop bleeding. NHS-1 and NHS-2
are synthetic, biodegradable [10,19] and do not contain any
blood products, collagens, or biological contaminants that
may be present in human- or animal-derived hemostatic
agents such as fibrin glue [1,8,10,14,20]. They can be applied
directly onto, or into, a wound without the concern that the
material may expand, thus reducing the risk of secondary
tissue damage as well as the problems caused by constricted
blood flow. In our previous brain studies [21] we looked for
evidence of the production of prion-like substances or fibril
tangles in animals that had the material implanted in their
brain for as long as 6 months but found none. Furthermore,
the breakdown products of NHS-1 are amino acids, which
can be used by the body as tissue building blocks for the
repair of the injury [21]. Independent third-party testing of the
material found no pyrogenicity, which has been found with
some other hemostatic agents, and no systemic coagulation or
other safety issues in animals [33].
The exact mechanism for the hemostasis reported here
is not fully understood, but we have uncovered several
clues. First, we know that the hemostasis is not explainable
by clotting. Blood clots are produced after injury, but do
not begin to form until 1 to 2 minutes have elapsed, de-
pending upon the status and coagulation history of the
patient [6,12,34].
Second, the electron micrographs show no evidence of
platelet aggregation at the interface of the material and wound
site. That arginine inhibits platelet aggregation suggests that
the arginine in NHS-1 plays a role in this effect [4,35-37];
this seems to be consistent with our data. The NHS-1 and
NHS-2 solutions appear to self-assemble into a barrier,
stemming the flow of blood and facilitating the movement of
adjacent cells to repair the injured site [21].
Third, in our experiments the NHS-1 and NHS-2 solutions
easily filled in and conformed to the irregular shapes of the
wounds before assembling, as shown in the electron micro-
graphs. We believe this tight contact is crucial to the
hemostatic action because of the size of the self-assembling
peptide units. The micrographs also showed that the material
does not cause the RBCs to lyse, apparently protecting them
from normal degradation when exposed to the air.
Fourth, we do not believe that the hemostasis can be
explained by gelation kinetics. One would think that a stifferED
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gel would be more effective for higher pressure bleeders;
however, we found the opposite to be true. TM-3, which is
from the same family of peptides as NHS-1 and NHS-2, and
is the stiffest of the three self-assembling peptides tested, did
not arrest bleeding; it fractured at the tissue interface and
within the resultant gel. We surmise that TM-3 may have
4fractured because of (1) the pulsations of the liver and (2)
4the inability of the material to flex with the tissue as blood
4pumped through the organ. This is similar to the fracturing
4of an artery when grown in a laminar flow environment and
4then transplanted to a pulsed environment. The cells line up
4along the direction of flow, unlike the natural helical coil
4[38-41] seen in a pulsed environment, which allows for
4expansion and contraction, without splitting, as blood
4moves though the artery. Conversely, NHS-1 and NHS-2
4were able to flex with the tissue.
4Finally, NHS-2, the most pliable of the three materials,
4seemed to perform identically to NHS-1, probably as a
4result of their similar structure and modulus.
4With this discovery the ability to speedily achieve
4hemostasis will reduce radically the quantity of blood needed
4during surgery of the future. As much as 50% of surgical time
4can be spent packing wounds to reduce or control bleeding.
4The NHS solutions may represent a step change in
4technology and could revolutionize bleeding control during
4surgery and trauma; however, they still require clinical testing
4before they can be used in humans.4Acknowledgments
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